Study of SY-9453 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has progressed or is not responding to standard treatments, or there is no standard treatment available.
- A recent test shows your tumor has lost both copies of a gene called MTAP (or you are willing to provide a tissue sample for this testing).
- You are able to carry out daily activities with little or no help (ECOG score 0 or 1).
- Your kidney, liver, and blood counts are within acceptable limits based on recent lab tests.
- You have not had certain other cancer treatments within the past few weeks, and any side effects from past treatments have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called HSK41959 combined with standard cancer therapy for people whose tumors have a specific genetic change (MTAP deletion). The goal is to see if the combination is safe and works better against advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This trial tests an investigational drug called HS-10587 for people with advanced solid tumors that have a specific genetic change (MTAP deletion) and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.